Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Juvenile idiopathic arthritis

*

* Not a rare disease

Other Names for this Disease

  • Arthritis, juvenile rheumatoid
  • Juvenile arthritis
  • Juvenile chronic arthritis
  • Juvenile rheumatoid arthritis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Juvenile idiopathic arthritis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Tocilizumab
Trade Name
(Manufacturer Name)
Actemra
(Genentech, Inc)
Indication
The FDA has approved this product to be used in this manner.
Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.
More Information about this product Drug Information Portal

Generic Name Ilaris
Trade Name
(Manufacturer Name)
Canakinumab
(Novartis Pharmaceuticals Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older. Also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.
More Information about this product Drug Information Portal

Generic Name Etanercept
Trade Name
(Manufacturer Name)
Enbrel®
(Amgen)
Indication
The FDA has approved this product to be used in this manner.
Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Adalimumab
Trade Name
(Manufacturer Name)
Humira®
(AbbVie Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of Juvenile Idiopathic Arthritis. Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Meloxicam
Trade Name
(Manufacturer Name)
Mobic®
(no longer avail)
Indication
The FDA has approved this product to be used in this manner.
For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Arthritis, juvenile rheumatoid
  • Juvenile arthritis
  • Juvenile chronic arthritis
  • Juvenile rheumatoid arthritis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.